Approval · Notice of Compliance 32984 · 2024
INTELENCE: Notice of Compliance 32984
Issued March 28, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32984
- Date
- March 28, 2024
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to Product Monograph (PM) to reflect discontinuation of the 25 mg tablet and to remove information related to HIV transmission from the Patient Medication Information (PMI) section.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| INTELENCE | Not yet assigned | — |
Medicinal ingredients
- ETRAVIRINE 100 MG per TAB
- ETRAVIRINE 200 MG per TAB